Načítá se...
A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals
Ebola virus (EBOV) causes a severe hemorrhagic fever with case fatality rates of up to 90%, for which no antiviral therapies are available. Antiviral screening is hampered by the fact that development of cytopathic effect, the easiest means to detect infection with wild-type EBOV, is relatively slow...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3787978/ https://ncbi.nlm.nih.gov/pubmed/23751367 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2013.05.017 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|